Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-90 SIRT and SBRT in Hepatic Malignancy
NCT04518748Phase 1Active, not recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Sep 2020
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of yttrium-90 in liver cancer, sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Change in Child-Turcotte-Pugh (CTP) score >= 2 points from baseline at 6 months, Incidence of toxicities of grade 3 or higher at 6 months and 1 more. Started Sep 2020; status: active, not recruiting.
02
Drugs
yttrium-90
03
Conditions
liver cancer
Beyond the preview
Go deeper on NCT04518748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04518748.